6K9.F CONTEXT THERAPEUT.DL-001

Healthcare Biotechnology Frankfurt Exchange
0.1650 EUR
Close of Nov 11, 2026
0.1060 3.12
Market cap
EUR 15.2M
P/E
-
P/B
0.40x
ROE
-132.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6K9.F undervalued?

Graham number

The Graham number of CONTEXT THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CONTEXT THERAPEUT.DL-001 fundamental analysis

No fundamental analysis for CONTEXT THERAPEUT.DL-001 yet.

CONTEXT THERAPEUT.DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CONTEXT THERAPEUT.DL-001

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The comp…

Full company profile